It has emerged that the sensitivity of a cancer cell to BCL-2 inhibition depends, at least in part, due to the quantity of pro-apoptotic proteins that are bound by the BCL-2 molecule [95,96,97]. This evidence concerns the gene BCL2 and cancer.